Sjogren Syndrome: Clinical Trials

9 trials for Sjogren Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 not yet recruiting, 3 recruiting, 2 completed, 1 terminated. 9 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Not yet recruiting 3, Recruiting 3, Completed 2, Terminated 1
Phase 13Completed 1, Not yet recruiting 1, Recruiting 1

Follow Sjogren Syndrome: new trials by email Literature Review of Sjogren Syndrome trials Research Report on Sjogren Syndrome

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease
Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis
Phase 2Not yet recruitingInstituto de Oftalmología Fundación Conde de Valenciana382026-12-012026-06-26
Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome
exosomes derived from human umbilical cord mesenchymal stem cells, Mesenchymal Stem Cells (MSC), Placebo - Sjogren Syndrome, Xerostomia
Phase 2Not yet recruitingBanu Erkal302026-12-012026-09-24
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
Phase 2RecruitingArtiva Biotherapeutics, Inc.902025-07-092026-07-31
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2RecruitingPeking University Third Hospital92025-07-012026-09-22
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy
Phase 2RecruitingPeking University People's Hospital502024-12-262025-04-02
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
Ianalumab - Sjogren Syndrome
Phase 2CompletedNovartis Pharmaceuticals212022-07-272026-02-02
A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)
MHV370, Placebo - Sjogren Syndrome, Mixed Connective Tissue Disease
Phase 2TerminatedNovartis Pharmaceuticals302021-11-302024-10-09
Green Tea Lozenges for the Management of Dry Mouth
MighTeaFlow, Xylitol - Xerostomia, Sjogren Syndrome
Phase 1 / Phase 2CompletedAugusta University602011-03-012015-03-18

Narrower conditions

Sjogren's Syndrome (9)  ·  Myositis (4)  ·  Scleroderma, Systemic (4)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)  ·  Xerostomia (3)  ·  Antiphospholipid Syndrome (2)  ·  Dry Eye Syndromes (2)  ·  Arthritis, Rheumatoid (1)  ·  Behcet Syndrome (1)  ·  Immunoglobulin G4-Related Disease (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Mixed Connective Tissue Disease (1)  ·  Purpura, Thrombotic Thrombocytopenic (1)  ·  Scleroderma, Diffuse (1)

Broader conditions

Arthritis (9)  ·  Autoimmune Diseases (9)  ·  Connective Tissue Diseases (9)  ·  Eye Diseases (9)  ·  Immune System Diseases (9)  ·  Joint Diseases (9)  ·  Lacrimal Apparatus Diseases (9)  ·  Mouth Diseases (9)  ·  Musculoskeletal Diseases (9)  ·  Rheumatic Diseases (9)  ·  Salivary Gland Diseases (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Stomatognathic Diseases (9)  ·  Arthritis, Rheumatoid (8)  ·  Dry Eye Syndromes (7)

Interventions

Aspartame (1)  ·  Infliximab (1)  ·  Loteprednol Etabonate (1)  ·  Xylitol (1)  ·  ianalumab (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Peking University Third Hospital (2)  ·  Artiva Biotherapeutics, Inc. (1)  ·  Augusta University (1)  ·  Banu Erkal (1)  ·  Instituto de Oftalmología Fundación Conde de Valenciana (1)  ·  Peking University People's Hospital (1)

Countries

China (3)  ·  France (2)  ·  Germany (2)  ·  Poland (2)  ·  Spain (2)  ·  United States (2)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Hungary (1)  ·  Italy (1)  ·  Mexico (1)  ·  Portugal (1)  ·  Romania (1)  ·  Serbia (1)  ·  Taiwan (1)

Top investigators

Banu Erkal, Resident (1)  ·  Enrique Graue-Hernandez, MD, MSc (1)  ·  Michael Saddekni, M.D., PgDip, BCMAS (1)  ·  Scott S De Rossi, DMD (1)  ·  Yavuz Selim Pata, Professor (1)  ·  Zhanguo Li (1)

Results publications

PMID 25240992, PMID 40747756, PMID 40787733, PMID 41726564

NIH funding

2023 (1)